Biological and Pharmaceutical Bulletin · 2003 · 39 citations · 16 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyMolecular OncologyOcular PharmacologyAngiogenesisAngiogenesis In CancerCorneal VascularizationMedicinal PlantsAngiogenic ResponseEndothelial Cell MigrationEndothelial MigrationEndothelial ProliferationEndothelial Tube FormationNeovascularizationVascular Endothelial Growth FactorVascular Endothelial Growth Factor Inhibition
cis-Hinokiresinol (CHR) is a norlignan constituent from Anemarrhena asphodeloides BUNGE (Liliaceae), which shows hyaluronidase inhibitory activity. In the present studies, we have demonstrated that CHR selectively inhibited endothelial cell proliferation compared with cancer cells, and especially basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation. Furthermore, endothelial cell migration and tube formation, two important steps in the angiogenic process, were also inhibited by CHR. Moreover, CHR reduced the vessel growth induced by VEGF in the mouse corneal neovascularization model. These results suggest that CHR may prove useful for the development of a novel angiogenesis inhibitor.
16
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Donald E. Ingber, Takeshi Fujita, SHOJI KISHIMOTO et al. · Nature · 1990 · 1.3K citations
Medicine, Oncology, Pharmacology +14
The Biology of Vascular Endothelial Growth Factor
Napoleone Ferrara · Endocrine Reviews · 1997 · 1.2K citations · Full text
Angiogenesis Induced by Degradation Products of Hyaluronic Acid
David C. West, Ian Hampson, Frank Arnold et al. · Science · 1985 · 1.1K citations
T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations
Medicine, Oncology, Pharmacology +16